Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT03976375
Registration number
NCT03976375
Ethics application status
Date submitted
3/06/2019
Date registered
6/06/2019
Date last updated
8/03/2024
Titles & IDs
Public title
Efficacy and Safety of Pembrolizumab (MK-3475) With Lenvatinib (E7080/MK-7902) vs. Docetaxel in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease (PD) After Platinum Doublet Chemotherapy and Immunotherapy (MK-7902-008/E7080-G000-316/LEAP-008)
Query!
Scientific title
A Phase 3, Multicenter, Randomized, Open-label Trial to Compare the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Lenvatinib (E7080/MK-7902) Versus Docetaxel in Previously Treated Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) and Progressive Disease (PD) After Platinum Doublet Chemotherapy and Immunotherapy (LEAP-008)
Query!
Secondary ID [1]
0
0
MK-7902-008
Query!
Secondary ID [2]
0
0
7902-008
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Metastatic Non-Small Cell Lung Cancer
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Lung - Mesothelioma
Query!
Cancer
0
0
0
0
Query!
Lung - Non small cell
Query!
Cancer
0
0
0
0
Query!
Lung - Small cell
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Other interventions - Pembrolizumab
Treatment: Drugs - Lenvatinib
Treatment: Drugs - Docetaxel
Experimental: Pembrolizumab+Lenvatinib - Participants receive pembrolizumab at 200 mg, every 3 weeks (Q3W) via intravenous (IV) infusion on Day 1 of each 21-day cycle, in combination with lenvatinib at 20 mg, once daily (QD) via oral capsule. Pembrolizumab will be administered for up to 35 treatment cycles (~2 years). Lenvantinib will be administered until progressive disease or unacceptable toxicity.
Active Comparator: Docetaxel - Participants receive docetaxel at 75 mg/m^2, Q3W via IV infusion over 1-hour infusion on Day 1 of each 21-day cycle. Docetaxel will be administered until progressive disease or unacceptable toxicity.
Experimental: Lenvatinib Monotherapy - Participants receive lenvatinib at 24 mg, QD via oral capsule. Lenvantinib will be administered until progressive disease or unacceptable toxicity.
Other interventions: Pembrolizumab
IV infusion of pembrolizumab at 200 mg
Treatment: Drugs: Lenvatinib
Oral capsules (unit strength: 4 and 10 mg) at 20 mg or 24 mg total daily dose.
Treatment: Drugs: Docetaxel
IV infusion of docetaxel at 75 mg/m^2.
Query!
Intervention code [1]
0
0
Other interventions
Query!
Intervention code [2]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Overall Survival (OS)
Query!
Assessment method [1]
0
0
OS is defined as the time from randomization to the date of death due to any cause.
Query!
Timepoint [1]
0
0
Up to ~48 months
Query!
Primary outcome [2]
0
0
Progression-free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)
Query!
Assessment method [2]
0
0
PFS is defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurs first. Per RECIST 1.1, PD is defined as =20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of =5 mm. Note: The appearance of one or more new lesions is also considered PD. PFS will be assessed by blinded independent central review (BICR) per RECIST 1.1, modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ.
Query!
Timepoint [2]
0
0
Up to ~36 months
Query!
Secondary outcome [1]
0
0
Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) - Pembrolizumab+Lenvatinib vs. Docetaxel
Query!
Assessment method [1]
0
0
ORR is defined as the percentage of participants who have a Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions). ORR will be assessed by BICR per RECIST 1.1, modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ.
Query!
Timepoint [1]
0
0
Up to ~18 months
Query!
Secondary outcome [2]
0
0
Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) - Pembrolizumab+Lenvatinib vs. Lenvatinib Monotherapy
Query!
Assessment method [2]
0
0
ORR is defined as the percentage of participants who have a Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions). ORR will be assessed by BICR per RECIST 1.1, modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ.
Query!
Timepoint [2]
0
0
Up to ~36 months
Query!
Secondary outcome [3]
0
0
Duration of Response (DOR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)
Query!
Assessment method [3]
0
0
DOR is defined as the time from first documented evidence of Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) until disease progression or death due to any cause, whichever occurs first. DOR will be assessed by BICR per RECIST 1.1, modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ.
Query!
Timepoint [3]
0
0
Up to ~48 months
Query!
Secondary outcome [4]
0
0
Number of Participants Experiencing an Adverse Event (AE)
Query!
Assessment method [4]
0
0
An AE is any untoward medical occurrence in a clinical study participant that is temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who experience an AE will be presented.
Query!
Timepoint [4]
0
0
Up to ~79 months
Query!
Secondary outcome [5]
0
0
Number of Participants Discontinuing Study Treatment Due to an AE
Query!
Assessment method [5]
0
0
The number of participants who discontinue study treatment due to an AE will be presented.
Query!
Timepoint [5]
0
0
Up to ~79 months
Query!
Secondary outcome [6]
0
0
Change from Baseline in European Organization for Research and Treatment (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Combined Global Health Status / Quality of Life (Items 29 & 30) Scale Combined Score
Query!
Assessment method [6]
0
0
The EORTC QLQ-C30 is a 30-item questionnaire developed to assess the quality of life (QoL) of cancer patients, including a combined global health status (GHS)/QoL (Items 29 and 30) scale. For each item, scores range from 0-100, with higher scores indicating higher GHS/QoL. Per protocol, scores for items 29 and 30 will be averaged to compute a combined GHS/QoL scale score. Change from baseline in the combined GHS/QoL scale score will be presented.
Query!
Timepoint [6]
0
0
Baseline and Week 12
Query!
Secondary outcome [7]
0
0
Change from Baseline in EORTC Quality of Life Questionnaire Lung Cancer Module 13 (QLQ-LC13) Cough (Item 31) Scale Score
Query!
Assessment method [7]
0
0
Used in combination with QLQ-C30, the EORTC QLQ-LC13 is a supplemental lung cancer-specific module, including a single-item scale score for cough (Item 31). For this item, individual responses to the question "How much did you cough?" are given on a 4-point scale (1=Not at all; 4=Very much). Scores are transformed to a range from 0-100, with a lower score indicating a better outcome. The change from baseline in the EORTC QLQ-LC13 cough (Item 31) scale score will be presented.
Query!
Timepoint [7]
0
0
Baseline and Week 12
Query!
Secondary outcome [8]
0
0
Change from Baseline in EORTC QLQ-LC13 Chest Pain (Item 40) Scale Score
Query!
Assessment method [8]
0
0
Used in combination with QLQ-C30, the EORTC QLQ-LC13 is a supplemental lung cancer-specific module, including a single-item scale score for chest pain (Item 40). For this item, individual responses to the question "Have you had pain in your chest?" are given on a 4-point scale (1=Not at all; 4=Very much). Scores are transformed to a range from 0-100, with a lower score indicating a better outcome. The change from baseline in the EORTC QLQ-LC13 chest pain (Item 40) scale score will be presented.
Query!
Timepoint [8]
0
0
Baseline and Week 12
Query!
Secondary outcome [9]
0
0
Change from Baseline in EORTC QLQ-C30 Dyspnea (Item 8) Scale Score
Query!
Assessment method [9]
0
0
The EORTC QLQ-C30 is a 30-item questionnaire developed to assess the QoL of cancer patients, including a single-item scale score for dyspnea (Item 8). For this item, individual responses to the question "Were you short of breath?" are given on a 4-point scale (1=Not at all; 4=Very much). Scores are transformed to a range from 0-100, with a lower score indicating a better outcome. The change from baseline in the EORTC QLQ-C30 dyspnea (Item 8) scale score will be presented.
Query!
Timepoint [9]
0
0
Baseline and Week 12
Query!
Secondary outcome [10]
0
0
Change from Baseline in EORTC QLQ-C30 Physical Functioning (Items 1 to 5) Scale Combined Score
Query!
Assessment method [10]
0
0
The EORTC QLQ-C30 is a 30-item questionnaire developed to assess the QoL of cancer patients, including a physical functioning (PF) scale (Items 1 to 5). The PF scale consists of participant responses to 5 questions regarding performance of daily activities [1) strenuous activities; 2) long walks; 3) short walks; 4) bed/chair rest; and 5) needing help with eating, dressing, washing themselves or using the toilet]. Overall PF scores range from 0 to 100, with a lower score indicating a better outcome. The change from Baseline in the EORTC QLQ-C30 PF (Items 1 to 5) scale combined score will be presented.
Query!
Timepoint [10]
0
0
Baseline and Week 12
Query!
Secondary outcome [11]
0
0
Time to True Deterioration (TTD) in EORTC QLQ-C30 Combined Global Health Status / Quality of Life (Items 29 & 30) Scale Combined Score
Query!
Assessment method [11]
0
0
The EORTC-QLQ-C30 is a 30-item questionnaire developed to assess the QoL of cancer patients, including a combined GHS/QoL (Items 29 and 30) scale. The TTD in the combined GHS/QoL (Items 29 & 30) scale combined score will be presented, defined as the time to first onset of a =10 point decrease from baseline.
Query!
Timepoint [11]
0
0
Up to ~48 months
Query!
Secondary outcome [12]
0
0
Time to True Deterioration (TTD) in EORTC QLQ-LC13 Cough (Item 31) Scale Score
Query!
Assessment method [12]
0
0
Used in combination with QLQ-C30, the EORTC QLQ-LC13 is a supplemental lung cancer-specific module, including a single-item scale score for cough (Item 31). The TTD in EORTC QLQ-LC13 cough (Item 31) scale score will be presented, defined as the time to first onset of a =10 point decrease from baseline.
Query!
Timepoint [12]
0
0
Up to ~48 months
Query!
Secondary outcome [13]
0
0
Time to True Deterioration (TTD) in EORTC QLQ-LC13 Chest Pain (Item 40) Scale Score
Query!
Assessment method [13]
0
0
Used in combination with QLQ-C30, the EORTC QLQ-LC13 is a supplemental lung cancer-specific module, including a single-item scale score for chest pain (Item 40). The TTD in EORTC QLQ-LC13 chest pain (Item 40) scale score will be presented, defined as the time to first onset of a =10 point decrease from baseline.
Query!
Timepoint [13]
0
0
Up to ~48 months
Query!
Secondary outcome [14]
0
0
Time to True Deterioration (TTD) in EORTC QLQ-C30 Dyspnea (Item 8) Scale Score
Query!
Assessment method [14]
0
0
The EORTC QLQ-C30 is a 30-item questionnaire developed to assess the QoL of cancer patients, including a single-item scale score for dyspnea (Item 8). The TTD in dyspnea (Item 8) scale score will be presented, defined as the time to first onset of a =10 point decrease from baseline.
Query!
Timepoint [14]
0
0
Up to ~48 months
Query!
Secondary outcome [15]
0
0
Time to True Deterioration (TTD) in EORTC QLQ-C30 Physical Functioning (Items 1 to 5) Scale Combined Score
Query!
Assessment method [15]
0
0
The EORTC QLQ-C30 is a 30-item questionnaire developed to assess the QoL of cancer patients, including a physical functioning (PF) scale (Items 1 to 5). The TTD in PF (Items 1 to 5) scale combined score will be presented, defined as the time to first onset of a =10 point decrease from baseline.
Query!
Timepoint [15]
0
0
Up to ~48 months
Query!
Eligibility
Key inclusion criteria
- Has a histologically or cytologically confirmed diagnosis of metastatic squamous or
nonsquamous NSCLC (Stage IV: M1a, M1b, M1c).
- Has PD on treatment with one prior anti-PD-1/PD-L1 monoclonal antibody (mAb)
administered either as monotherapy or in combination with other checkpoint inhibitors
or other therapies.
- Retreatment with the same anti-PD-L1/PD-L1 mAb is acceptable in the overall
course of treatment
- Has PD during/after platinum doublet chemotherapy for metastatic disease.
- Has confirmation that EGFR-, ALK-, or ROS1-directed therapy is not indicated as
primary therapy (documentation of absence of tumor-activating EGFR mutations [eg,
DEL19 or L858R], and absence of ALK and ROS1 gene rearrangements OR presence of a
K-ras mutation).
- Has submitted pre-study imaging that confirmed evidence of PD following initiation of
an anti-PD-1/PD-L1 inhibitor.
- Has at least 1 measurable lesion by computerized tomography (CT) or magnetic resonance
imaging (MRI) per RECIST 1.1, as determined by the local site assessment.
- Has provided tumor tissue for PD-L1 biomarker analysis from an archival sample
(defined as: from initial diagnosis of NSCLC and prior to receiving immunotherapy
[antiPD-1/PD-L1], from the primary lesion or a metastatic lesion).
- Has provided prior to allocation tissue from a newly obtained formalin-fixed sample
from a new biopsy (defined as: after completion of immunotherapy [anti-PD-1/PD-L1] and
before receiving a randomization number), of a tumor lesion not previously irradiated.
- Has Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 within 7
days before the first dose of study intervention but before randomization.
- Has a life expectancy of at least 3 months.
- Male participants receiving pembrolizumab ± lenvatinib or lenvatinib must agree to
refrain from donating sperm, and either 1) be abstinent from heterosexual intercourse;
or 2) follow contraceptive guidance during the treatment period or 7 days after the
last dose of lenvatinib. Male participants receiving docetaxel agree to adhere to the
same conditions during the treatment period and for =90 days after the last dose of
study treatment.
- Female participants must not be pregnant, not be breastfeeding, and not be a woman of
child-bearing potential (WOCBP). If a WOCBP, agrees to not donate eggs and either use
contraception, or be abstinent from heterosexual intercourse during the treatment
period and for =120 days after the last dose of pembrolizumab or 30 days after the
last dose of lenvatinib, whichever occurs last. If a WOCBP receiving docetaxel, agrees
to adhere to the same conditions during the treatment period and for =30 days after
the last dose of study treatment.
- Has adequately controlled blood pressure (BP) with or without antihypertensive
medications, defined as BP =150/90 mm Hg and no change in antihypertensive medications
within 1 week before randomization.
- If participant received major surgery or radiation therapy of >30 Gy, they have
recovered from the toxicity and/or complications from the intervention.
- Has adequate organ function.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Has received docetaxel as monotherapy or in combination with other therapies.
- Has received lenvatinib as monotherapy or in combination with an anti-PD-1/PD-L1 mAb.
- Has received: 1) radiotherapy within 2 weeks before the first dose of study treatment;
or 2) lung radiation therapy >30 Gy within 6 months before the first dose of study
treatment.
- Has received a live vaccine within 30 days before the first dose of study treatment.
- Has clinically significant hemoptysis or tumor bleeding within 2 weeks before the
first dose of study treatment.
- Has radiographic evidence of intratumoral cavitation, encasement, or invasion of a
major blood vessel.
- Has clinically significant cardiovascular impairment within 12 months of the first
dose of study treatment.
- Has a history of a gastrointestinal condition or procedure that may affect oral
absorption of study treatment.
- Has a pre-existing =Grade 3 gastrointestinal or non-gastrointestinal fistula.
- Is currently participating in a clinical trial and receiving study therapy or
participated in a study of an investigational agent within 4 weeks of the first dose
of study treatment.
- Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy
or any other form of immunosuppressive therapy within 7 days before the first dose of
study treatment.
- Has a known history of an additional malignancy, except if the participant has
undergone potentially curative therapy with no evidence of disease recurrence for 3
years since initiation of that therapy.
- Has known active central nervous system metastases and/or carcinomatous meningitis.
- Has severe hypersensitivity to pembrolizumab and/or any of its excipients.
- Has a sensitivity to any of the excipients contained in lenvatinib and/or docetaxel.
- Has an active autoimmune disease that has required systemic treatment in the past 2
years.
- Has a history of (noninfectious) pneumonitis that required systemic steroids or
current pneumonitis/interstitial lung disease.
- Has an active infection requiring systemic therapy.
- Has a known history of human immunodeficiency virus (HIV) infection.
- Has a known history of hepatitis B reactive or known active hepatitis C virus
infection.
- Has active tuberculosis.
- Has a known psychiatric or substance abuse disorder that would interfere with the
participant's ability to cooperate with the requirements of the study.
- Is pregnant or breastfeeding or expecting to conceive or father children within the
projected duration of the study, starting with the screening visit through at least
120 days after the last dose of pembrolizumab or lenvatinib, or 90 days (male
participants) or 30 days (for female participants) after the last dose of docetaxel.
- Has had an allogeneic tissue/solid organ transplant.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Active, not recruiting
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
26/06/2019
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
18/09/2024
Query!
Actual
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
422
Query!
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,VIC
Query!
Recruitment hospital [1]
0
0
Blacktown Hospital ( Site 0004) - Blacktown
Query!
Recruitment hospital [2]
0
0
Port Macquarie Base Hospital ( Site 0003) - Port Macquarie
Query!
Recruitment hospital [3]
0
0
Westmead Hospital ( Site 0005) - Westmead
Query!
Recruitment hospital [4]
0
0
Southern Medical Day Care Centre ( Site 0001) - Wollongong
Query!
Recruitment hospital [5]
0
0
Princess Alexandra Hospital - Division of Cancer Services ( Site 0002) - Woolloongabba
Query!
Recruitment hospital [6]
0
0
Calvary Central Districts Hospital ( Site 0007) - Elizabeth Vale
Query!
Recruitment hospital [7]
0
0
Bendigo Cancer Centre ( Site 0008) - Bendigo
Query!
Recruitment postcode(s) [1]
0
0
2148 - Blacktown
Query!
Recruitment postcode(s) [2]
0
0
2444 - Port Macquarie
Query!
Recruitment postcode(s) [3]
0
0
2145 - Westmead
Query!
Recruitment postcode(s) [4]
0
0
2500 - Wollongong
Query!
Recruitment postcode(s) [5]
0
0
4102 - Woolloongabba
Query!
Recruitment postcode(s) [6]
0
0
5112 - Elizabeth Vale
Query!
Recruitment postcode(s) [7]
0
0
3552 - Bendigo
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
California
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Florida
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Kentucky
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Louisiana
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Maryland
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Massachusetts
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Montana
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
New Jersey
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
New York
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Ohio
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Oregon
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Pennsylvania
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Tennessee
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Texas
Query!
Country [15]
0
0
Argentina
Query!
State/province [15]
0
0
Buenos Aires
Query!
Country [16]
0
0
Argentina
Query!
State/province [16]
0
0
Caba
Query!
Country [17]
0
0
Argentina
Query!
State/province [17]
0
0
Santa Fe
Query!
Country [18]
0
0
Canada
Query!
State/province [18]
0
0
Manitoba
Query!
Country [19]
0
0
Canada
Query!
State/province [19]
0
0
Ontario
Query!
Country [20]
0
0
Canada
Query!
State/province [20]
0
0
Quebec
Query!
Country [21]
0
0
Colombia
Query!
State/province [21]
0
0
Antioquia
Query!
Country [22]
0
0
Colombia
Query!
State/province [22]
0
0
Atlantico
Query!
Country [23]
0
0
Colombia
Query!
State/province [23]
0
0
Cesar
Query!
Country [24]
0
0
Colombia
Query!
State/province [24]
0
0
Cordoba
Query!
Country [25]
0
0
Colombia
Query!
State/province [25]
0
0
Distrito Capital De Bogota
Query!
Country [26]
0
0
Colombia
Query!
State/province [26]
0
0
Valle Del Cauca
Query!
Country [27]
0
0
France
Query!
State/province [27]
0
0
Calvados
Query!
Country [28]
0
0
France
Query!
State/province [28]
0
0
Hauts-de-Seine
Query!
Country [29]
0
0
France
Query!
State/province [29]
0
0
Maine-et-Loire
Query!
Country [30]
0
0
France
Query!
State/province [30]
0
0
Pas-de-Calais
Query!
Country [31]
0
0
France
Query!
State/province [31]
0
0
Provence-Alpes-Cote-d Azur
Query!
Country [32]
0
0
France
Query!
State/province [32]
0
0
Sarthe
Query!
Country [33]
0
0
France
Query!
State/province [33]
0
0
Paris
Query!
Country [34]
0
0
Germany
Query!
State/province [34]
0
0
Baden-Wurttemberg
Query!
Country [35]
0
0
Germany
Query!
State/province [35]
0
0
Nordrhein-Westfalen
Query!
Country [36]
0
0
Germany
Query!
State/province [36]
0
0
Thuringen
Query!
Country [37]
0
0
Germany
Query!
State/province [37]
0
0
Berlin
Query!
Country [38]
0
0
Greece
Query!
State/province [38]
0
0
Attiki
Query!
Country [39]
0
0
Greece
Query!
State/province [39]
0
0
Ioannina
Query!
Country [40]
0
0
Greece
Query!
State/province [40]
0
0
Thessaloniki
Query!
Country [41]
0
0
Hungary
Query!
State/province [41]
0
0
Borsod-Abauj-Zemplen
Query!
Country [42]
0
0
Hungary
Query!
State/province [42]
0
0
Fejer
Query!
Country [43]
0
0
Hungary
Query!
State/province [43]
0
0
Gyor-Moson-Sopron
Query!
Country [44]
0
0
Hungary
Query!
State/province [44]
0
0
Jasz-Nagykun-Szolnok
Query!
Country [45]
0
0
Hungary
Query!
State/province [45]
0
0
Pest
Query!
Country [46]
0
0
Hungary
Query!
State/province [46]
0
0
Veszprem
Query!
Country [47]
0
0
Hungary
Query!
State/province [47]
0
0
Budapest
Query!
Country [48]
0
0
Israel
Query!
State/province [48]
0
0
Beer Sheva
Query!
Country [49]
0
0
Israel
Query!
State/province [49]
0
0
Haifa
Query!
Country [50]
0
0
Israel
Query!
State/province [50]
0
0
Jerusalem
Query!
Country [51]
0
0
Israel
Query!
State/province [51]
0
0
Kfar-Saba
Query!
Country [52]
0
0
Israel
Query!
State/province [52]
0
0
Petah Tikva
Query!
Country [53]
0
0
Israel
Query!
State/province [53]
0
0
Ramat Gan
Query!
Country [54]
0
0
Israel
Query!
State/province [54]
0
0
Tel Aviv
Query!
Country [55]
0
0
Italy
Query!
State/province [55]
0
0
Monza E Brianza
Query!
Country [56]
0
0
Italy
Query!
State/province [56]
0
0
Roma
Query!
Country [57]
0
0
Italy
Query!
State/province [57]
0
0
Sicilia
Query!
Country [58]
0
0
Italy
Query!
State/province [58]
0
0
Torino
Query!
Country [59]
0
0
Italy
Query!
State/province [59]
0
0
Avellino
Query!
Country [60]
0
0
Italy
Query!
State/province [60]
0
0
Bari
Query!
Country [61]
0
0
Italy
Query!
State/province [61]
0
0
Catania
Query!
Country [62]
0
0
Italy
Query!
State/province [62]
0
0
Milano
Query!
Country [63]
0
0
Italy
Query!
State/province [63]
0
0
Pavia
Query!
Country [64]
0
0
Italy
Query!
State/province [64]
0
0
Perugia
Query!
Country [65]
0
0
Japan
Query!
State/province [65]
0
0
Kanagawa
Query!
Country [66]
0
0
Japan
Query!
State/province [66]
0
0
Miyagi
Query!
Country [67]
0
0
Japan
Query!
State/province [67]
0
0
Osaka
Query!
Country [68]
0
0
Japan
Query!
State/province [68]
0
0
Chiba
Query!
Country [69]
0
0
Japan
Query!
State/province [69]
0
0
Niigata
Query!
Country [70]
0
0
Japan
Query!
State/province [70]
0
0
Tokyo
Query!
Country [71]
0
0
Korea, Republic of
Query!
State/province [71]
0
0
Chungbuk
Query!
Country [72]
0
0
Korea, Republic of
Query!
State/province [72]
0
0
Kyonggi-do
Query!
Country [73]
0
0
Korea, Republic of
Query!
State/province [73]
0
0
Seoul
Query!
Country [74]
0
0
Portugal
Query!
State/province [74]
0
0
Lisboa
Query!
Country [75]
0
0
Portugal
Query!
State/province [75]
0
0
Porto
Query!
Country [76]
0
0
Puerto Rico
Query!
State/province [76]
0
0
Manati
Query!
Country [77]
0
0
Puerto Rico
Query!
State/province [77]
0
0
Ponce
Query!
Country [78]
0
0
Puerto Rico
Query!
State/province [78]
0
0
San Juan
Query!
Country [79]
0
0
Russian Federation
Query!
State/province [79]
0
0
Baskortostan, Respublika
Query!
Country [80]
0
0
Russian Federation
Query!
State/province [80]
0
0
Krasnoyarskiy Kray
Query!
Country [81]
0
0
Russian Federation
Query!
State/province [81]
0
0
Moskva
Query!
Country [82]
0
0
Russian Federation
Query!
State/province [82]
0
0
Omskaya Oblast
Query!
Country [83]
0
0
Russian Federation
Query!
State/province [83]
0
0
Sankt-Peterburg
Query!
Country [84]
0
0
Spain
Query!
State/province [84]
0
0
Asturias
Query!
Country [85]
0
0
Spain
Query!
State/province [85]
0
0
Barcelona
Query!
Country [86]
0
0
Spain
Query!
State/province [86]
0
0
Cantabria
Query!
Country [87]
0
0
Spain
Query!
State/province [87]
0
0
Las Palmas
Query!
Country [88]
0
0
Spain
Query!
State/province [88]
0
0
Madrid
Query!
Country [89]
0
0
Spain
Query!
State/province [89]
0
0
Valenciana, Comunitat
Query!
Country [90]
0
0
Spain
Query!
State/province [90]
0
0
Jaen
Query!
Country [91]
0
0
United Kingdom
Query!
State/province [91]
0
0
East Riding Of Yorkshire
Query!
Country [92]
0
0
United Kingdom
Query!
State/province [92]
0
0
England
Query!
Country [93]
0
0
United Kingdom
Query!
State/province [93]
0
0
Leicestershire
Query!
Country [94]
0
0
United Kingdom
Query!
State/province [94]
0
0
London, City Of
Query!
Country [95]
0
0
United Kingdom
Query!
State/province [95]
0
0
Scotland
Query!
Country [96]
0
0
United Kingdom
Query!
State/province [96]
0
0
Warwickshire
Query!
Country [97]
0
0
United Kingdom
Query!
State/province [97]
0
0
Birmingham
Query!
Country [98]
0
0
United Kingdom
Query!
State/province [98]
0
0
Leeds
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Merck Sharp & Dohme LLC
Query!
Address
Query!
Country
Query!
Other collaborator category [1]
0
0
Commercial sector/Industry
Query!
Name [1]
0
0
Eisai Inc.
Query!
Address [1]
0
0
Query!
Country [1]
0
0
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This study will evaluate the efficacy and safety of pembrolizumab (MK-3475) with lenvatinib
(E7080/MK-7902) vs. docetaxel in participants with metastatic non-small cell lung cancer
(NSCLC) and progressive disease (PD) after platinum doublet chemotherapy and treatment with
one prior anti-PD-1/PD-L1 monoclonal antibody (mAb). The primary hypotheses of this study are
that pembrolizumab + lenvatinib (compared with docetaxel) prolongs: 1) overall survival (OS);
and progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors Version
1.1 (RECIST 1.1) based on blinded independent central review (BICR).
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT03976375
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Medical Director
Query!
Address
0
0
Merck Sharp & Dohme LLC
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT03976375
Download to PDF